rentradВестник рентгенологии и радиологииJournal of radiology and nuclear medicine0042-46762619-0478Limited Liability Company "LUCHEVAYA DIAGNOSTIKA", Russian Association of Radiologists10.20862/0042-4676-2024-105-2-107-113rentrad-873Research ArticleОБЗОРЫREVIEWSВзгляд радиотерапевта на роль современной диагностической визуализации в предлучевой подготовке пациентов с олигометастатической болезнью к проведению конформной радиотерапииRadiotherapist’s View on the Role of Current Diagnostic Imaging in Pre-Radiation Preparation of Patients with Oligometastatic Disease for Conformal Radiotherapyhttps://orcid.org/0000-0003-1106-6358ПаньшинГ. А.PanshinG. A.

Паньшин Георгий Александрович, д. м. н., профессор, гл. науч. сотр. лаборатории лучевой терапии и комплексных методов  лечения онкологических заболеваний научно-исследовательского отдела комплексной диагностики заболеваний и радиотерапии 

 

Georgiy А. Panshin, Dr. Med. Sc., Professor, Senior Resеаrcher, Laboratory of Radiation Therapy and Complex Methods of Cancer Treatment,  Research Department of Complex Diagnostics of Diseases and Radiotherapy

ul. Profsoyuznaya, 86, Moscow, 117997

g.a.panshin@mail.ruhttps://orcid.org/0000-0001-5994-0468НудновН. В.NudnovN. V.

Нуднов Николай Василевич, д. м. н., профессор, зам. директора по научной работе, заведующий научно-исследовательским отделом комплексной диагностики заболеваний и радиотерапии; профессор кафедры рентгенологии и радиологии 

 

Nikolay V. Nudnov, Dr. Med. Sc., Professor, Deputy Director for Scientific Work, Head of Research Department of Complex Diagnostics of Diseases and Radiotherapy; Professor, Chair of Radiology and Nuclear Medicine

ul. Profsoyuznaya, 86, Moscow, 117997

ul. Barrikadnaya, 2/1, str.1, Moscow, 125993

ФГБУ «Российский научный центр рентгенорадиологии» Минздрава РоссииРоссияRussian Scientific Center of RoentgenoradiologyRussian FederationФГБУ «Российский научный центр рентгенорадиологии» Минздрава России; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Scientific Center of Roentgenoradiology; Russian Medical Academy of Continuing Professional EducationRussian Federation2024071020241052107113Copyright © Паньшин Г.А., Нуднов Н.В., 20242024Паньшин Г.А., Нуднов Н.В.Panshin G.A., Nudnov N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.russianradiology.ru/jour/article/view/873

Диагностическая визуализация олигометастатической болезни является сложной задачей, поскольку требует определения точной локорегионарной стадии основного заболевания и оценки состояния всего тела с точки зрения возможного диффузного распространения отдаленных метастазов, что нередко подразумевает сочетание различных инструментальных методов. В каждом конкретном случае визуализационный метод выбирается в зависимости от типа новообразования, времени проведения диагностики, возможного реализованного ранее этапа специального противоопухолевого лечения, а также индивидуального риска развития отдаленных метастазов, наиболее характерного для данного вида опухолевого процесса. На сегодняшний день наряду с некоторыми диагностическими приемами, которые ранее постоянно использовались в повседневной практике, но постепенно утрачивают клиническое применение, наиболее часто проводятся компьютерная томография (КТ) с контрастным усилением, магнитно-резонансная томография, а также метаболическая и специфическая визуализация рецепторов, например совмещенная с КТ позитронно-эмиссионная томография с 18F-фтордезоксиглюкозой, – отдельно или в различных комбинациях.

Diagnostic imaging of oligometastatic disease is a difficult task, since it requires determining the exact locoregional stage of the underlying disease and assessing the condition of the entire body in terms of possible diffuse spread of distant metastases, which presupposes a fairly frequent combination of various instrumental methods. In each specific case, a more accurate imaging method is chosen depending on the type of tumor, time of diagnosis, possible previously implemented stage of special antitumor treatment, as well as the individual risk of developing distant metastases, the most characteristic for this type of tumor process. Today, along with some diagnostic techniques that were previously constantly used in everyday practice, but are gradually losing their long-standing clinical application, such imaging methods as contrastenhanced computed tomography (CT), magnetic resonance imaging, as well as metabolic and specific receptor imaging, for example, CT combined with positron emission tomography with 18F-fluorodeoxyglucose, are most commonly performed, alone or in various combinations.

олигометастатическая болезньпредлучевая диагностическая визуализациядистанционная стереотаксическая аблационная радиотерапия телаoligometastatic diseasepre-radiation diagnostic imagingexternal stereotactic ablative radiotherapy of the bodyReferencesHellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995; 13(1): 8–10. https://doi.org/10.1200/JCO.1995.13.1.8.Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995; 13(1): 8–10. https://doi.org/10.1200/JCO.1995.13.1.8.Паньшин Г.А. Олигометастатическая болезнь и дистанционная стереотаксическая абляционная радиотерапия тела (общие вопросы). Вестник Российского научного центра рентгенорадиологии. 2023; 23(3): 32–43.Panshin GA. Oligometastatic disease and remote stereotactic ablative radiotherapy of the body (general issues). Vestnik of the Russian Scientific Center of Roentgenoradiology. 2023; 23(3): 32–43 (in Russ).]D’Onofrio M, Crosara S, De Robertis R. Contrast-enhanced ultrasound of focal liver lesions. AJR Am J Roentgenol. 2015; 205(1): W56–66. https://doi.org/10.2214/AJR.14.14203.D’Onofrio M, Crosara S, De Robertis R. Contrast-enhanced ultrasound of focal liver lesions. AJR Am J Roentgenol. 2015; 205(1): W56–66. https://doi.org/10.2214/AJR.14.14203.O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: an update. World J Radiol. 2015; 7(8): 202–11. https://doi.org/10.4329/wjr.v7.i8.202.O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: an update. World J Radiol. 2015; 7(8): 202–11. https://doi.org/10.4329/wjr.v7.i8.202.Liu B, Gao S, Li S. A comprehensive comparison of CT, MRI, positron emission tomography or positron emission tomography/CT, and diffusion weighted imaging-MRI for detecting the lymph nodes metastases in patients with cervical cancer: a meta-analysis based on 67 studies. Gynecol Obstet Invest. 2017; 82(3): 209–22. https://doi.org/10.1159/000456006.Liu B, Gao S, Li S. A comprehensive comparison of CT, MRI, positron emission tomography or positron emission tomography/CT, and diffusion weighted imaging-MRI for detecting the lymph nodes metastases in patients with cervical cancer: a meta-analysis based on 67 studies. Gynecol Obstet Invest. 2017; 82(3): 209–22. https://doi.org/10.1159/000456006.deSouza NM, Tempany CM. A risk-based approach to identifying oligometastatic disease on imaging. Int J Cancer. 2019; 144(3): 422–30. https://doi.org/10.1002/ijc.31793.deSouza NM, Tempany CM. A risk-based approach to identifying oligometastatic disease on imaging. Int J Cancer. 2019; 144(3): 422–30. https://doi.org/10.1002/ijc.31793.Lo SS, Gore EM, Bradley JD, et al. ACR Appropriateness Criteria® pre-irradiation evaluation and management of brain metastases. J Palliat Med. 2014; 17(8): 880–6. https://doi.org/10.1089/jpm.2014.9417.Lo SS, Gore EM, Bradley JD, et al. ACR Appropriateness Criteria® pre-irradiation evaluation and management of brain metastases. J Palliat Med. 2014; 17(8): 880–6. https://doi.org/10.1089/jpm.2014.9417.Barzilai O, Laufer I, Yamada Y, et al. Integrating evidence-based medicine for treatment of spinal metastases into a decision framework: neurologic, oncologic, mechanicals stability, and systemic disease. J Clin Oncol. 2017; 35(21): 2419–27. https://doi.org/10.1200/JCO.2017.72.7362.Barzilai O, Laufer I, Yamada Y, et al. Integrating evidence-based medicine for treatment of spinal metastases into a decision framework: neurologic, oncologic, mechanicals stability, and systemic disease. J Clin Oncol. 2017; 35(21): 2419–27. https://doi.org/10.1200/JCO.2017.72.7362.Mizukami Y, Ueda S, Mizumoto A, et al. Diffusion-weighted magnetic resonance imaging for detecting lymph node metastasis of rectal cancer. World J Surg. 2011; 35(4): 895–9. https://doi.org/10.1007/s00268-011-0986-x.Mizukami Y, Ueda S, Mizumoto A, et al. Diffusion-weighted magnetic resonance imaging for detecting lymph node metastasis of rectal cancer. World J Surg. 2011; 35(4): 895–9. https://doi.org/10.1007/s00268-011-0986-x.Lecouvet FE. Whole-body MR imaging: musculoskeletal applications. Radiology. 2016; 279(2): 345–65. https://doi.org/10.1148/radiol.2016142084.Lecouvet FE. Whole-body MR imaging: musculoskeletal applications. Radiology. 2016; 279(2): 345–65. https://doi.org/10.1148/radiol.2016142084.Jouvet JC, Thomas L, Thomson V, et al. Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PETCT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study. J Eur Acad Dermatol Venereol. 2014; 28(2): 176–85. https://doi.org/10.1111/jdv.12078.Jouvet JC, Thomas L, Thomson V, et al. Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PETCT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study. J Eur Acad Dermatol Venereol. 2014; 28(2): 176–85. https://doi.org/10.1111/jdv.12078.Perez-Lopez R, Lorente D, Blackledge MD, et al. Volume of bone metastasis assessed with whole-body diffusion-weighted imaging is associated with overall survival in metastatic castration-resistant prostate cancer. Radiology. 2016; 280(1): 151–60. https://doi.org/10.1148/radiol.2015150799.Perez-Lopez R, Lorente D, Blackledge MD, et al. Volume of bone metastasis assessed with whole-body diffusion-weighted imaging is associated with overall survival in metastatic castration-resistant prostate cancer. Radiology. 2016; 280(1): 151–60. https://doi.org/10.1148/radiol.2015150799.Chong A, Hwang I, Ha JM, et al. Application of bone scans for prostate cancer staging: which guideline shows better result? Can Urol Assoc J. 2014; 8(7–8): E515–9. https://doi.org/10.5489/cuaj.2054.Chong A, Hwang I, Ha JM, et al. Application of bone scans for prostate cancer staging: which guideline shows better result? Can Urol Assoc J. 2014; 8(7–8): E515–9. https://doi.org/10.5489/cuaj.2054.Van den Wyngaert T, Strobel K, Kampen WU, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging. 2016; 43(9): 1723–38. https://doi.org/10.1007/s00259-016-3415-4.Van den Wyngaert T, Strobel K, Kampen WU, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging. 2016; 43(9): 1723–38. https://doi.org/10.1007/s00259-016-3415-4.Palma DA, Haasbeek CJ, Rodrigues GB, et al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer. 2012; 12: 305. https://doi.org/10.1186/1471-2407-12-305.Palma DA, Haasbeek CJ, Rodrigues GB, et al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer. 2012; 12: 305. https://doi.org/10.1186/1471-2407-12-305.Olson R, Liu M, Bergman A, et al. Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5. BMC Cancer. 2018; 18(1): 954. https://doi.org/10.1186/s12885-018-4859-7.Olson R, Liu M, Bergman A, et al. Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5. BMC Cancer. 2018; 18(1): 954. https://doi.org/10.1186/s12885-018-4859-7.Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABRCOMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019; 19(1): 816. https://doi.org/10.1186/s12885-019-5977-6.Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABRCOMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019; 19(1): 816. https://doi.org/10.1186/s12885-019-5977-6.Olson R, Jiang W, Liu M, et al. Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer: primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical trial. JAMA Oncol. 2022; 8(11): 1644–50. https://doi.org/10.1001/jamaoncol.2022.4394.Olson R, Jiang W, Liu M, et al. Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer: primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical trial. JAMA Oncol. 2022; 8(11): 1644–50. https://doi.org/10.1001/jamaoncol.2022.4394.Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020; 148: 157–66. https://doi.org/10.1016/j.radonc.2020.04.003.Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020; 148: 157–66. https://doi.org/10.1016/j.radonc.2020.04.003.Galgano SJ, McDonald AM, West JT, Rais-Bahrami S. Defining oligometastatic disease in the new era of PSMA-PET imaging for primary staging of prostate cancer. Cancers (Basel). 2022; 14(14): 3302. https://doi.org/10.3390/cancers14143302.Galgano SJ, McDonald AM, West JT, Rais-Bahrami S. Defining oligometastatic disease in the new era of PSMA-PET imaging for primary staging of prostate cancer. Cancers (Basel). 2022; 14(14): 3302. https://doi.org/10.3390/cancers14143302.Artigas C, Diamand R, Shagera QA, et al. Oligometastatic disease detection with 68Ga-PSMA-11 PET/CT in hormonesensitive prostate cancer patients (HSPC) with biochemical recurrence after radical prostatectomy: predictive factors and clinical impact. Cancers (Basel). 2021; 13(19): 4982. https://doi.org/10.3390/cancers13194982.Artigas C, Diamand R, Shagera QA, et al. Oligometastatic disease detection with 68Ga-PSMA-11 PET/CT in hormonesensitive prostate cancer patients (HSPC) with biochemical recurrence after radical prostatectomy: predictive factors and clinical impact. Cancers (Basel). 2021; 13(19): 4982. https://doi.org/10.3390/cancers13194982.Christ SM, Pohl K, Willmann J, et al. Patterns of metastatic spread and tumor burden in unselected cancer patients using PET imaging: implications for the oligometastatic spectrum theory. Clin Transl Radiat Oncol. 2024; 45: 100724. https://doi.org/10.1016/j.ctro.2024.100724.Christ SM, Pohl K, Willmann J, et al. Patterns of metastatic spread and tumor burden in unselected cancer patients using PET imaging: implications for the oligometastatic spectrum theory. Clin Transl Radiat Oncol. 2024; 45: 100724. https://doi.org/10.1016/j.ctro.2024.100724.Christ SM, Pohl K, Muehlematter UJ, et al. Imaging-based prevalence of oligometastatic disease: a single-center crosssectional study. Int J Radiat Oncol Biol Phys. 2022; 114(4): 596–602. https://doi.org/10.1016/j.ijrobp.2022.06.100.Christ SM, Pohl K, Muehlematter UJ, et al. Imaging-based prevalence of oligometastatic disease: a single-center crosssectional study. Int J Radiat Oncol Biol Phys. 2022; 114(4): 596–602. https://doi.org/10.1016/j.ijrobp.2022.06.100.McCarthy M, Francis R, Tang C, et al. A multicenter prospective clinical trial of 68Gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: oligometastatic rate and distribution compared with standard imaging. Int J Radiat Oncol Biol Phys. 2019; 104(4): 801–8. https://doi.org/10.1016/j.ijrobp.2019.03.014.McCarthy M, Francis R, Tang C, et al. A multicenter prospective clinical trial of 68Gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: oligometastatic rate and distribution compared with standard imaging. Int J Radiat Oncol Biol Phys. 2019; 104(4): 801–8. https://doi.org/10.1016/j.ijrobp.2019.03.014.Romero A, Serna-Blasco R, Calvo V, Provencio M. Use of liquid biopsy in the care of patients with non-small cell lung cancer. Curr Treat Options Oncol. 2021; 22(10): 86. https://doi.org/10.1007/s11864-021-00882-9.Romero A, Serna-Blasco R, Calvo V, Provencio M. Use of liquid biopsy in the care of patients with non-small cell lung cancer. Curr Treat Options Oncol. 2021; 22(10): 86. https://doi.org/10.1007/s11864-021-00882-9.Zhang L, Riethdorf S, Wu G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res. 2012; 18(20): 5701–10. https://doi.org/10.1158/1078-0432.CCR-12-1587.Zhang L, Riethdorf S, Wu G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res. 2012; 18(20): 5701–10. https://doi.org/10.1158/1078-0432.CCR-12-1587.Cescon DW, Bratman SV, Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer. 2020; 1(3): 276–90. https://doi.org/10.1038/s43018-020-0043-5.Cescon DW, Bratman SV, Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer. 2020; 1(3): 276–90. https://doi.org/10.1038/s43018-020-0043-5.

The authors declare that there are no conflicts of interest present.